This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.

Phase III Study is to Evaluate the efficacy of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
Extensive-stage Small Cell Lung Cancer
DRUG: AL3810|DRUG: carboplatin + etoposide|DRUG: Placebo
Phase II:adverse event(AE)/serious adverse event(SAE), AE/SAE to find the recommended dose of AL3810, From the date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|Phase III:1.PFS, 1. Duration of Progression-Free Survival (PFS) as Assessed by the Independent Review Committee Using RECIST v1.1, From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 56 months
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.

Phase III Study is to Evaluate the efficacy of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.